Acceleration of c-myc-induced hepatocarcinogenesis by co-expression of transforming growth factor (TGF)-α in transgenic mice is associated with TGF-β1 signaling disruption

American Journal of Pathology

Volumn 154, Issue 6, 1999, Pages 1693-1700

  Santoni Rugiu, Eric ^a,b,c   Jensen, Michael R ^a   Factor, Valentina M ^a   Thorgeirsson, Snorri S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PISA   (Italy)

^c DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; GENE DISRUPTION; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LIVER CANCER; LIVER CARCINOGENESIS; MOUSE; NONHUMAN; NORTHERN BLOTTING; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TRANSGENIC MOUSE;

EID: 0032981837     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)65425-9     Document Type: Article

References (51)

1. Grisham JW: Interspecies comparison of liver carcinogenesis: implications for cancer risk assessment. Carcinogenesis 1997, 18:59-81
2. Santoni-Rugiu E, Nagy P, Jensen MR, Factor VM, Thorgeirsson SS: Evolution of neoplastic development in the liver of transgenic mice co-expressing c-myc and transforming growth factor-α. Am J Pathol 1996, 149:407-428
3. Santoni-Rugiu E, Preisegger KH, Kiss A, Audolfsson T, Shiota G, Schmidt EV, Thorgeirsson SS: Inhibition of neoplastic development in the liver by hepatocyte growth factor in a transgenic mouse model. Proc Natl Acad Sci USA 1996, 93:9577-9582
4. Murakami H, Sanderson N, Nagy P, Marino P, Merlino GT, Thorgeirsson SS: Transgenic mouse model for synergistic effects of nuclear oncogenes and growth factors in tumorigenesis: interaction of c-myc and transforming growth factor α in hepatic oncogenesis. Cancer Res 1993, 53:1719-1723
5. Santoni-Rugiu E, Jensen MR, Thorgeirsson SS: Disruption of the pRb/E2F pathway and inhibition of apoptosis are major oncogenic events in liver constitutively expressing c-myc and transforming growth factor α. Cancer Res 1998, 58:123-134
6. Fausto N, Laird AD, Webber EM: Role of growth factors and cytokines in hepatic regeneration. FASEB J 1995, 9:1527-1536
7. Schulte-Hermann R, Grausl-Krapp B, Bursch W: Apoptosis and hepatocarcinogenesis. Liver Regeneration and Carcinogenesis: Cellular and Molecular Mechanisms. Edited by Jirtle RL. New York, Academic Press, 1995, pp 141-178
8. Factor VM, Kao C-Y, Santoni-Rugiu E, Woitach JT, Jensen MR, Thorgeirsson SS: Constitutive expression of mature transforming growth factor β1 in the liver accelerates hepatocarcinogenesis in transgenic mice. Cancer Res 1997, 57:2089-2095
9. Alexandrow MG, Moses HL: Transforming growth factor β and cell cycle regulation. Cancer Res 1995, 55:1452-1457
10. Sugiyama A, Nagaki M, Shidoji Y, Moriwaki H, Muto Y: Regulation of cell cycle-related genes in rat hepatocytes by transforming growth factor β1. Biochem Biophys Res Commun 1997, 238:539-543
11. INK4b is a potential effector of cell cycle arrest mediated by TGF-β. Nature 1994, 371:257-261
12. Kipl, a cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest. Genes Dev 1994, 8:9-22
13. Kipl, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994, 78:59-66
14. Slingerland JM, Hengst L, Pan CH, Alexander D, Stampfer MR, Reed SI: A novel inhibitor of cyclin-Cdk activity detected in transforming growth factor β-arrested epithelial cells. Mol Cell Biol 1994, 14:3683-3694
15. Reynisdottir I, Polyak K, Iavarone A, Massagué J: Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-β. Genes Dev 1995, 9:1831-1845
16. Laiho M, DeCaprio JA, Ludlow JW, Livingston DM, Massagué J: Growth inhibition by TGF-β linked to suppression of retinoblastoma protein phosphorylation. Cell 1990, 62:175-185
17. Mulder KM, Zhong Q, Choi HG, Humphrey LE, Brattain MG: Inhibitory effects of transforming growth factor β1 on mitogenic response, transforming growth factor α, and c-myc in quiescent, well-differentiated colon carcinoma cells. Cancer Res 1990, 50:7581-7586
18. Ko TC, Sheng HM, Reisman D, Thompson EA, Beauchamp RD: Transforming growth factor β1 inhibits cyclin D1 expression in intestinal epithelial cells. Oncogene 1995, 10:177-184
19. Schwarz JK, Bassing CH, Kovesdi I, Datto MB, Blazing M, Gorge S, Wang XF, Nevins JR: Expression of the E2F1 transcription factor overcomes type β transforming growth factor-mediated growth suppression. Proc Natl Acad Sci USA 1995, 92:483-487
20. Okamoto A, Jiang W, Kim S-J, Spillare EA, Stoner GD, Weinstein IB, Harris CC: Overexpression of human cyclin D1 reduces the transforming growth factor β (TGF-β) type II receptor and growth inhibition by TGF-β1 in an immortalized human esophageal epithelial cell line. Proc Natl Acad Sci USA 1994, 91:11576-11580
21. Quelle DE, Ashum RA, Hannon GJ, Rehberger PA, Trono D, Richter KH, Walker C, Beach D, Sherr CJ, Serrano M: Cloning and characterization of murine p16INK4A and p15INK4B genes. Oncogene 1995, 11:635-645
22. Heldin CH, Miyazona K, ten Dijke P: TGFβ signaling from cell membrane to nucleus through SMAD proteins. Nature 1997, 390:465-471
23. Massagué J: TGF-β signal transduction. Annu Rev Biochem 1998, 67:753-791
24. Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, Fan RS, Zborowska E, Kinzler KW, Vogelstein B, Brattain M, Willson JKV: Inactivation of the type II TGFR-β receptor in colon cancer cells with microsatellite instability. Science 1995, 268:1336-1338
25. Bedossa P, Peltier E, Terris B, Franco D, Poynard T: Transforming growth factor-β1 (TGF-β1)and TGF-β1 receptors in normal, cirrhotic, and neoplastic human livers. Hepatology 1995, 21:760-766
26. Kiss A, Wang N-J, Xie J-P, Thorgeirsson SS: Analysis of transforming growth factor (TGF)-α/epidermal growth factor receptor, hepatocyte growth factor/c-met, TGF-β receptor type II, and p53 expression in human hepatocellular carcinomas. Clin Cancer Res 1997, 3:1059-1066
27. Böttinger EP, Jakubczak JL, Haines DC, Bagnall K, Wakefield LM: Transgenic mice overexpressing a dominant-negative mutant type II transforming growth factor β receptor show enhanced tumorigenesis in the mammary gland and lung in response to the carcinogen 7, 12-dimethylbenz[a]anthracene. Cancer Res 1997, 57:5564-5570
28. Amendt C, Schirmacher P, Weber H, Blessing M: Expression of dominant negative type II TGF-β receptor in mouse skin results in an increase in carcinoma incidence and acceleration of carcinoma development. Oncogene 1998, 17:25-34
29. Inagaki M, Moustakas A, Lin HY, Lodish HF, Carr BI: Growth inhibition by transforming growth factor-β (TGF-β) type I is restored in TGF-β-resistant hepatoma cells after expression of TGF-β receptor type II cDNA. Proc Natl Acad Sci USA 1993, 90:5359-5363
30. Chang J, Park K, Bang Y-J, Kim WS, Kim D, Kim S-J: Expression of transforming growth factor β type II receptor reduces tumorigenicity in human gastric cancer cells. Cancer Res 1997, 57:2856-2859
31. Kim IY, Ahn H-J, Zelner DJ, Shaw JW, Lang S, Kato M, Oefelein MG, Miyazono K, Nemeth JA, Kozlowski JM, Lee C: Loss of expression of transforming growth factor β type I and type II receptors correlates with tumor grade in human prostate cancer tissues. Clin Cancer Res 1996, 2:1255-1261
32. Okamoto M, Oyasu R: Overexpression of transforming growth factor β type I receptor abolishes malignant phenotype of a rat bladder carcinoma cell line. Cell Growth Differ 1997, 8:921-926
33. Grady WM, Rajput A, Myeroff L, Liu DF, Kwon K, Willis J, Markowitz S: Mutation of the type II transforming growth factor-β receptor is coincident with the transformation of human colon adenomas to malignant carcinomas. Cancer Res 1998, 58:3101-3104
34. Wang S, Souza RF, Kong D, Yin J, Smolinski KN, Zou T-T, Frank T, Young J, Flanders KC, Sugimura H, Abraham JM, Meltzer SJ: Deficient transforming growth factor-β1 activation and excessive insulin-like growth factor II (IGFII) expression in IGFII receptor-mutant tumors. Cancer Res 1997, 57:2543-2546
35. Yamada T, De Souza A, Finkelstein S, Jirtle RL: Loss of the gene encoding mannose 6-phosphate/insulin-like growth factor II receptor is an early event in liver carcinogenesis. Proc Natl Acad Sci USA 1997, 94:10351-10355
36. Mills JJ, Falls JG, De Souza A, Jirtle RL: Imprinted M6p/lgf2 receptor is mutated in rat liver tumors. Oncogene 1998, 16:2797-2802
37. Woitach JT, Zhang M, Niu CH, Thorgeirsson SS: A retinoblastoma-binding protein that affects cell-cycle control and confers transforming ability. Nature Genet 1998, 19:371-374
38. Albrecht JH, Poon RYC, Ahonen CL, Rieland BM, Deng C, Crary GS: Involvement of p21 and p27 in the regulation of CDK activity and cell-cycle progression in the regenerating liver. Oncogene 1998, 16:2141-2150
39. Fero ML, Randel E, Gurley KE, Roberts JM, Kemp CJ: The murine gene p27Kip/is haplo-insufficient for tumor suppression. Nature 1998, 396:1177-1180
40. Kipl is abrogated by c-Myc. EMBO J 1996, 15:6595-6604
41. Kipl protein: prognostic implications in primary breast cancer. Nature Med 1997, 3:227-230
42. Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, Jessup JM, Pagano M: Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nature Med 1997, 3:231-234
43. Esposito V, Baldi A, De Luca A, Groger AM, Loda M, Giordano GG, Caputi M, Baldi F, Pagano M, Giordano A: Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res 1997, 57:3381-3385
44. Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, Yew PR, Draetta GF, Rolfe M: Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995, 269:682-685
45. Kipl accumulation during the cell cycle. Science 1996, 271:1861-1864
46. Santoni-Rugiu E, Thorgeirsson SS: Transgenic animals as models for hepatocarcinogenesis. Liver Growth and Repair, Edited by Strain A, Diehl AM. New York, Chapman and Hall, 1998, pp 100-142
47. Kipl. J Cell Biol 1998, 142:557-571
48. Lloyd AC: Ras versus cyclin-dependent kinase inhibitors. Curr Opin Genet Dev 1998, 8:43-48
49. Kipl overexpression causes apoptotic death of mammalian cells. Oncogene 1997, 15: 2991-2997
50. Katayose Y, Kim M, Rakkar ANS, Cowan KH, Seth P: Promoting apoptosis: a novel activity associated with the cyclin-dependent kinase inhibitor p27. Cancer Res 1997, 57:5441-5445
51. Nakayama K, Ishida N, Shirane M, Inomata A, Inoue T, Shishido N, Horii I, Loh DY: Mice lacking p27(Kipl) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 1996, 85:707-720